United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility  testing ). dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prio

United States - English - NLM (National Library of Medicine)

sandoz inc - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - the penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see clinical pharmacology – susceptibility testing ). the penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus , therapy should not be continued with a penicillinase-resistant penicillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, d

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility  testing ) . dicloxacillin may be used to initiate therapy in suspected cases of resistant stap

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eugia pharma (malta) ltd. - flucloxacillin sodium monohydrate - eq. flucloxacillin 500 mg - powder for solution for injection/infusion - 500 mg - flucloxacillin 500 mg - flucloxacillin

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - flucloxacillin sodium monohydrate 272.6mg equivalent to flucloxacillin 250 mg;   - capsule - 250 mg - active: flucloxacillin sodium monohydrate 272.6mg equivalent to flucloxacillin 250 mg   excipient: colloidal silicon dioxide gelatin magnesium stearate

New Zealand - English - Medsafe (Medicines Safety Authority)

medra & pharma services limited - flucloxacillin sodium monohydrate 544mg equivalent to flucloxacillin 500 mg;  ;  ;  ;   - capsule - 500 mg - active: flucloxacillin sodium monohydrate 544mg equivalent to flucloxacillin 500 mg         excipient: magnesium stearate

New Zealand - English - Medsafe (Medicines Safety Authority)

hospira nz ltd - flucloxacillin sodium monohydrate 524.2mg equivalent to 500 mg flucloxicillin.;   - powder for injection - 500 mg - active: flucloxacillin sodium monohydrate 524.2mg equivalent to 500 mg flucloxicillin.  

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - flucloxacillin sodium monohydrate, quantity: 1088.1 mg (equivalent: flucloxacillin, qty 1000 mg) - injection, powder for - excipient ingredients: - for the treatment of confirmed or suspected staphylococcal infections and other gram-positive coccal infections. indications include pneumonia, osteomyelitis, skin and skin structure and wound infections, infected burns and cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - flucloxacillin sodium monohydrate, quantity: 544.1 mg (equivalent: flucloxacillin, qty 500 mg) - injection, powder for - excipient ingredients: - for the treatment of confirmed or suspected staphylococcal infections and other gram-positive coccal infections. indications include pneumonia, osteomyelitis, skin and skin structure and wound infections, infected burns and cellulitis.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - the penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see clinical pharmacology – susceptibility testing ). the penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dic